Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 29Carcinoma, Non-Small-Cell Lung 17Pancreatic Neoplasms 12Neoplasm Metastasis 9Stomach Neoplasms 7Lung Neoplasms 7Rectal Neoplasms 6Neoplasms 6Melanoma 6Esophageal Neoplasms 6Colonic Neoplasms 6Ovarian Neoplasms 4Gastrointestinal Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Site 2Liver Neoplasms 2Hypopharyngeal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Pancreatic Ductal 2Biliary Tract Neoplasms 2Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Diseases 1

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophagogastric Cancer × Pemetrexed × Gastrointestinal × Clear all
NCT02296671 2016-03-08

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Washington University School of Medicine

Phase 2 Withdrawn
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡